1.Clinical effects of San'ao Decoction combined with salbutamol on patients with cough variant asthma
Yan-Jun ZHANG ; Ju LIU ; Xiang-Cai KONG ; Ji-Chao JIN ; Ming-Xue BAI
Chinese Traditional Patent Medicine 2023;45(12):3954-3958
AIM To explore the clinical effects of San'ao Decoction combined with salbutamol on patients with cough variant asthma.METHODS Eighty patients were randomly assigned into control group(40 cases)for 3-month administration of salbutamol,and observation group(40 cases)for 3-month administration of both San'ao Decoction and mifepristone.The changes in clinical efficacy,TCM syndrome scores,serum MMP-9,VEGF and sex hormones(E2,FSH,PRL)and incidence of adverse reactions were detected.The changes in clinical efficacy,EOS,SIgG4,TIgE,Eotaxin,NKA,LTD4,IL-27,SP,R5-R20,Fres,R5,Zrs,PEF diurnal variation rate,FEF25,PEF,ACT score,PAQLQ score,recurrence rate and incidence of adverse reactions were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05),along with lower recurrence rate(P<0.05).After the treatment,the two groups displayed decreased EOS,TIgE,Eotaxin,NKA,LTD4,SP,R5-R20,Fres,R5,Zrs and PEF diurnal variation rate(P<0.05),and increased SIgG4,IL-27,FEF25,PEF,ACT score,PAQLQ score(P<0.05),especially for the observation group(P<0.05).No significant difference in incidence of adverse reactions was found between the two groups(P>0.05).CONCLUSION For the patients with cough variant asthma,San'ao Decoction combined with salbutamol can improve EOS,TIgE,Eotaxin,SIgG4 levels and airway resistance indices,lung function indices,regulate neurogenic mediators,alleviate airway inflammation injury,enhance life quality,and reduce recurrence rate.
2.Biological Essence of Component Complexity in Herbal Medicine: Based on Changed Metabolism of Scutellaria baicalensis Under Drought Stress
Hong-wei DU ; Meng LI ; Zhi-hong LOU ; Wei CONG ; Yu GUAN ; Ling KONG ; Xiang-cai MENG
Chinese Journal of Experimental Traditional Medical Formulae 2021;27(24):148-156
Objective:To investigate the biological essence of the content variation of differential primary and secondary metabolites in fresh
3.Development and validation of a deep learning model to screen hypokalemia from electrocardiogram in emergency patients.
Chen-Xi WANG ; Yi-Chu ZHANG ; Qi-Lin KONG ; Zu-Xiang WU ; Ping-Ping YANG ; Cai-Hua ZHU ; Shou-Lin CHEN ; Tao WU ; Qing-Hua WU ; Qi CHEN
Chinese Medical Journal 2021;134(19):2333-2339
BACKGROUND:
A deep learning model (DLM) that enables non-invasive hypokalemia screening from an electrocardiogram (ECG) may improve the detection of this life-threatening condition. This study aimed to develop and evaluate the performance of a DLM for the detection of hypokalemia from the ECGs of emergency patients.
METHODS:
We used a total of 9908 ECG data from emergency patients who were admitted at the Second Affiliated Hospital of Nanchang University, Jiangxi, China, from September 2017 to October 2020. The DLM was trained using 12 ECG leads (lead I, II, III, aVR, aVL, aVF, and V1-6) to detect patients with serum potassium concentrations <3.5 mmol/L and was validated using retrospective data from the Jiangling branch of the Second Affiliated Hospital of Nanchang University. The blood draw was completed within 10 min before and after the ECG examination, and there was no new or ongoing infusion during this period.
RESULTS:
We used 6904 ECGs and 1726 ECGs as development and internal validation data sets, respectively. In addition, 1278 ECGs from the Jiangling branch of the Second Affiliated Hospital of Nanchang University were used as external validation data sets. Using 12 ECG leads (leads I, II, III, aVR, aVL, aVF, and V1-6), the area under the receiver operating characteristic curve (AUC) of the DLM was 0.80 (95% confidence interval [CI]: 0.77-0.82) for the internal validation data set. Using an optimal operating point yielded a sensitivity of 71.4% and a specificity of 77.1%. Using the same 12 ECG leads, the external validation data set resulted in an AUC for the DLM of 0.77 (95% CI: 0.75-0.79). Using an optimal operating point yielded a sensitivity of 70.0% and a specificity of 69.1%.
CONCLUSIONS
In this study, using 12 ECG leads, a DLM detected hypokalemia in emergency patients with an AUC of 0.77 to 0.80. Artificial intelligence could be used to analyze an ECG to quickly screen for hypokalemia.
Artificial Intelligence
;
Deep Learning
;
Electrocardiography
;
Humans
;
Hypokalemia/diagnosis*
;
Retrospective Studies
4. Comparison of predicting scales for symptomatic intracranial hemorrhage after stroke thrombolysis with recombinant tissue plasminogen activator
Juehua ZHU ; Chunyan HAN ; Runnan LI ; Yun ZHOU ; Xiang TANG ; Dongxue DING ; Lulu ZHANG ; Hui WANG ; Yan KONG ; Xiuying CAI ; Qi FANG
Chinese Journal of Neurology 2019;52(12):1022-1030
Objective:
Symptomatic intracranial hemorrhage (sICH) is one of the severe complications of ischemic stroke thrombolysis. Several prognostic scales have been developed to predict the risk of sICH. The performance of seven scales was compared in a single center cohort.
Methods:
Data of patients with consecutive ischemic stroke who received 0.9 mg/kg intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis within 4.5 h time window from stroke onset were collected. Seven scales that can provide an estimate of risk of sICH were identified and evaluated: Hemorrhage After Thrombolysis (HAT), blood Sugar, Early infarct signs, (hyper) Dense cerebral artery sign, Age, National Institutes of Health (NIH) Stroke Scale (SEDAN), Stroke Prognostication using Age and NIH Stroke Scale (SPAN)-100, Safe Implementation of Thrombolysis in Stroke (SITS), Total Health Risks In Vascular Events (THRIVE), Glucose at presentation, Race (Asia), Age, Sex (male), systolic blood Pressure at presentation, and Severity of stroke at presentation (NIH Stroke Scale; GRASPS) and Multicenter Stroke Survey (MSS). The area under the receiver operating characteristic curve (AUROC) was calculated and Logistic regression and the Hosmer-Lemeshow test were also performed.
Results:
The current study included 293 patients, of whom 7.85% (23/293) had sICH by National Institute of Neurological Disorders and Stroke (SICHNINDS), 5.46% (16/293) by Europe Cooperative Acute Stroke Study Ⅱ (SICHECASSⅡ) and 4.44% (13/293) by Safe Implementation of Thrombolysis in Stroke (SICHSITS) criteria. SEDAN had the highest AUROC for predicting sICH: sICHNINDS: AUROC=0.843,
5.Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018).
Liang DAI ; Chung-Wah CHENG ; Ran TIAN ; Linda Ld ZHONG ; You-Ping LI ; Ai-Ping LYU ; An-Wen CHAN ; Hong-Cai SHANG ; Zhao-Xiang BIAN
Chinese journal of integrative medicine 2019;25(1):71-79
Traditional Chinese Medicine (TCM) is one of the oldest systems of medicine. More and more attention has been paid to TCM application, but the variable quality of clinical trials with TCM impedes its widespread acceptance. The Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 2013 Statement has established guidelines for designing clinical trials to ensure that the trial results are accurate and reliable. However, there are difficulties when applying SPIRIT 2013 Statement to trials with TCM, due to the unique theory and the characteristic of TCM intervention. An Extension to the original SPIRIT was developed to ensure the quality of trial design with TCM. As Chinese herbal formulae, acupuncture and moxibustion are common and representative interventions in TCM practice, the executive working group determined that the SPIRIT-TCM Extension focus on these three interventions. Extension was developed through initiation, 3 rounds of Delphi consensus survey, and finalizing expert meeting. Seven items from the SPIRIT 2013 Statement were modified, namely, "title", "background and rationale", "objectives", "eligibility criteria", "interventions", "outcomes", and "data collection methods". The Extension includes the introduction of the concept of TCM pattern and 3 major TCM interventions, with examples and explanations. The SPIRIT-TCM Extension 2018 provides suggestion for investigators in designing high quality TCM clinical trials. It is expected that wide dissemination and application of this extension ensure continuous improvement of TCM trial quality throughout the world.
Clinical Protocols
;
Clinical Trials as Topic
;
Humans
;
Medicine, Chinese Traditional
;
Research Design
6.Whether Syndrome Differentiation Affects Treatment Result: Study Protocol of MaZiRenWan () for Functional Constipation in A Randomized Controlled Trial.
Chung-Wah CHENG ; Li ZHANG ; Chen ZHAO ; Linda Ld ZHONG ; Li-Jie SHI ; Liang DAI ; Rui ZHENG ; Jing CHEN ; Ge LI ; Jing-Bo ZHAI ; Wai KUN ; Ai-Ping LU ; Hong-Cai SHANG ; Zhao-Xiang BIAN
Chinese journal of integrative medicine 2019;25(3):175-181
BACKGROUND:
Syndrome is one of the most important concepts in Chinese medicine (CM) theory. However, it was not well accounted in most of randomized controlled trials (RCTs).
OBJECTIVES:
To determine whether CM syndrome differentiation affects the treatment results, functional constipation (FC) was selected as a target disease, and MaZiRenWan (, MZRW), a classic CM formula commonly used for constipation with excessive heat syndrome, was selected for study.
METHODS:
It is an 18-week prospective double-blinded, doubledummy RCT, including 2-week run-in, 8-week treatment and 8-week post treatment follow-up. A total of 120 FC patients diagnosed as excessive heat syndrome will be recruited from the First Teaching Hospital of Tianjin University of Traditional Chinese Medicine and the Baokang Affiliated Hospital of Tianjin University of Traditional Chinese Medicine. Patients will be randomly allocated into fixed MZRW (f_MZRW) granule group, modified MZRW (m_MZRW) granule group or bisacodyl group. For m_MZRW group, no more than two herbal granules can be added according to the syndrome differentiation for individual participants. The primary end point is the mean of complete spontaneous bowel movements (CSBMs) per week during the treatment period. Secondary end points include mean of CSBMs per week during follow-up, stool form, global symptom improvement, constipation and constipation-related symptoms assessment, CM syndrome change, and reported adverse events.
DISCUSSION
This trial is designed to evaluate the effectiveness of these three interventions for FC patients with the CM syndrome of excessive heat, and to determine the change of CM syndrome and the progress of disease during the treatment course. The results are important to explore whether syndrome differentiation is important for the therapeutic effect of a formula on a disease. [Trial registration: Chinese Clinical Trial Registry (Reg No. ChiCTR-TRC-13003742); protocol version: MZRW/NSFC-81173363 (2015.05.04)].
Constipation
;
diagnosis
;
drug therapy
;
Double-Blind Method
;
Drugs, Chinese Herbal
;
therapeutic use
;
Humans
;
Medicine, Chinese Traditional
;
Outcome Assessment (Health Care)
;
Prospective Studies
;
Randomized Controlled Trials as Topic
7.Systematic Reviews/Meta-Analyses of Integrative Medicine in Chinese Need Regulation and Monitoring Urgently and Some Suggestions for Its Solutions.
Jia-Ying WANG ; Gui-Hua TIAN ; You-Ping LI ; Tai-Xiang WU ; Zhao-Xiang BIAN ; Liang DU ; Hong-Cai SHANG
Chinese journal of integrative medicine 2018;24(2):83-86
With the introduction and development of evidence-based medicine in China, it has been spread rapidly in the area of integrative medicine (IM) and has become a new unique discipline. During almost 20 years, as one of the most important parts of evidence-based IM, systematic review (SR)/meta-analysis (MA) of IM have shown a good development momentum in the aspects of quantity, depth, breadth and influence, but also face the harsh situation of the uncontrolled quantity and quality, especially for SRs in Chinese. Therefore, how to supervise and standardize this area effectively becomes a problem to be solved. Based on the experience both at home and abroad, the authors put forward several kinds of solutions for laying the foundation for further development such as promoting the registration system of SR/MA of IM, effectively setting up the regulatory platform of quality and quantity, launching professional training for SR/MA reviewers, forming qualification registration, developing the data transfer and sharing platform to realize the transparency of evidence process.
8.Retrospective analysis and discussion on 74 cases of adverse reactions of traditional Chinese medicine injection.
Yan WANG ; Li-Ping FAN ; Ju SONG ; Yue-Ping CAI ; Ting-Ting JINANG ; Yu-Guang WANG ; Xiang-Wen KONG ; Jia-Rui WU
China Journal of Chinese Materia Medica 2018;43(21):4347-4351
As a modern dosage form drug with rapid effect, traditional Chinese medicine (TCM) injection has been more and more used in clinical practice. Meanwhile the safety of TCM injection has attracted more and more attention. The retrospective analysis on 74 cases of adverse reaction of TCM injections collected from 2007 to 2016 in the Third Affiliated Hospital of Beijing University of Chinese Medicine showed that the proportion of men and women with adverse reactions was 0.54:1; the average age was 62.5 years old; 21 kinds of TCM injections were involved. Among them, the most reported were blood-regulating agents. The top four kinds of TCM injections with highest adverse drug reactions (ADRs) were Tanreqing injection, Danhong Injection, Shuxuening Injection and Xuesaitong for injection. The top three clinical manifestations of adverse reactions were lesions of skin and its appendages, damage of circulatory system and damage of nervous system. The potential causes of the adverse reactions of TCM injections were analyzed, and it was believed that individual difference, medicine, pharmaceutical excipients, solvent and TCM syndrome differentiation may be the main five causes for the adverse reactions of TCM injections. In order to reduce the adverse reactions of TCM injections, it is suggested that the clinical pharmacists should participate in the application management of TCM injections in the hospital; the production enterprises shall strengthen the whole life cycle management of the drugs; and at the same time, the drug control and administration authorities should improve the drug management methods constantly and encourage the development of TCM injections to the high quality level.
Drugs, Chinese Herbal
;
adverse effects
;
Female
;
Humans
;
Injections
;
adverse effects
;
Male
;
Medicine, Chinese Traditional
;
adverse effects
;
Middle Aged
;
Retrospective Studies
9.Toward Evidence-Based Chinese Medicine: Status Quo, Opportunities and Challenges.
Yao-Long CHEN ; Chen ZHAO ; Li ZHANG ; Bo LI ; Chuan-Hong WU ; Wei MU ; Jia-Ying WANG ; Ke-Hu YANG ; You-Ping LI ; Chiehfeng CHEN ; Yong-Yan WANG ; Chen WANG ; Zhao-Xiang BIAN ; Hong-Cai SHANG
Chinese journal of integrative medicine 2018;24(3):163-170
How to test the treatments of Chinese medicine (CM) and make them more widely accepted by practitioners of Western medicine and the international healthcare community is a major concern for practitioners and researchers of CM. For centuries, various approaches have been used to identify and measure the efficacy and safety of CM. However, the high-quality evidence related to CM that produced in China is still rare. Over the recent years, evidence-based medicine (EBM) has been increasingly applied to CM, strengthening its theoretical basis. This paper reviews the past and present state of CM, analyzes the status quo, challenges and opportunities of basic research, clinical trials, systematic reviews, clinical practice guidelines and clinical pathways and evidence-based education developed or conducted in China, pointing out how EBM can help to make CM more widely used and recognized worldwide.
Critical Pathways
;
Evidence-Based Medicine
;
Humans
;
Medicine, Chinese Traditional
;
Practice Guidelines as Topic
;
Randomized Controlled Trials as Topic
10.Targeting knockout of DMD gene exon51 in HEK293T cell based on CRISPR/Cas9 system
Shuang LI ; Shan-Shan MA ; Si-Ying CUI ; Su-Zhen QU ; Ao-Jie CAI ; Fang-Xia GUAN ; Xiang-Dong KONG
Basic & Clinical Medicine 2018;38(3):375-380
Objective To knockout the exon51 of DMD gene in HEK293T cells using the CRISPR/Cas9 system. Methods Design the target sequences of sgRNA and clone them into plasmid PX459 respectively; transfer these plasmids into HEK293T cell and extract the total genome DNA; test the activity of sgRNAs with surveyor assay, choose the most efficient one in each end;construct plasmid PX459-2sgRNA and transfer it into HEK293T cells;check whether the exon51 has been knocked known with PCR and T vector sequencing. Results 50% of HEK293T cells' DMD gene exon51 were knocked out,showing a high gene editing efficiency. Conclusions We successfully establish a platform to target knockout the exon51 of DMD gene and provide an important experimental basis for the treatment of DMD and other genetic diseases.

Result Analysis
Print
Save
E-mail